生物制剂与银屑病：节奏仍在继续。

Biologics and Psoriasis: The Beat Goes On.

作者信息

Kim Hee J, Lebwohl Mark G

机构信息

Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, 5th Floor, PO Box 1048, New York, NY 10029, USA.

出版信息

Dermatol Clin. 2019 Jan;37(1):29-36. doi: 10.1016/j.det.2018.07.004. Epub 2018 Nov 1.

DOI:10.1016/j.det.2018.07.004

PMID:30466686

Abstract

Psoriasis is a chronic, immune-mediated, inflammatory skin disease that requires long-term therapy for disease control. This article reviews data presented in clinical trials to evaluate and compare various characteristics of biologics that are currently approved for the treatment of psoriasis. Attributes of biological agents that are examined in this article include efficacy, long-term maintenance, overall safety, median time to onset of efficacy, adjustment for body weight, frequency of injections, indication for psoriatic arthritis, and safety in pregnancy. Here, we evaluate what the ideal choice of biological therapy may be for psoriasis patients with specific needs.

摘要

银屑病是一种慢性、免疫介导的炎症性皮肤病，需要长期治疗以控制病情。本文回顾了临床试验中呈现的数据，以评估和比较目前已获批用于治疗银屑病的各种生物制剂的特征。本文所考察的生物制剂的属性包括疗效、长期维持效果、总体安全性、起效的中位时间、体重调整、注射频率、银屑病关节炎的适应症以及孕期安全性。在此，我们评估对于有特定需求的银屑病患者而言，理想的生物治疗选择可能是什么。